November 2010
Worldwide Biotech;Nov2010, Vol. 22 Issue 11, p6
Trade Publication
This article reports on a prospective trial initiated by a global pharmaceutical firm to evaluate the impact of insulin guidelines developed by the Indian National Consensus Group in collaboration with Max Neeman International. The study is aimed at providing simple management to type II diabetes patients dependent on insulin. Particular focus is given to the study's scope in India, as well as its target patient enrollment figures. Also included are information on Max Neeman as a contract research organization in India.


Related Articles

  • Diabetes Care Austria 2009: Register an allgemeinmedizinischen Ordinationen für PatientInnen mit Typ 2 Diabetes mellitus in Österreich. Ludvik, Bernhard; Schernthaner, Guntram // Wiener Klinische Wochenschrift;Feb2012, Vol. 124 Issue 3/4, p69 

    Diabetes Care Austria was a nationwide data acquisition of type 2 diabetes treatment at Austrian general practitioners. A total of 5,385 general practitioners were contacted in the end of 2009; finally, 101 agreed to participate in the data collection. Out of all 9 Austrian provinces, a...

  • Management of Type 2 Diabetes.  // Current Medical Literature: Diabetes;2012, Vol. 29 Issue 2, p44 

    The article discusses studies on type 2 diabetes management. One study examined whether loss of fat, fluid or lean tissue caused the associated weight loss from the administration of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2). Another study focused on a post hoc...

  • The Effect of L-Arginin Supplementation on lipid profiles in patients with diabetes type 2. Asadi S.; H., Mozaffari Khosravi; Rahimi M.; Naghizadeh M. M. // Journal of Fasa University of Medical Sciences / Majallah-i Dani;Spring2014, Vol. 4 Issue 1, p99 

    Background & Objective: The prominent growth in the statistics of the patients with Diabetes Mellitus (DM) and the danger of its complication states a necessity to focus on finding new ways to control it. The present study then was performed to survey the effect of L-Arginin supplementation on...

  • NOVEL APPROACH OF MANAGEMENT OF DIABETES MELLITUS WITH DPP IV AND INCRETIN. Bhapkar, R.; Ganu, G.; Garud, A.; Kshirsagar, A. // Pharma Science Monitor;Jan2012, Vol. 3 Issue 1, p48 

    At the present time, DPP IV is considered one of the most promising therapeutic targets for the treatment of T2DM. A large number of clinical trials have shown that DPP IV inhibitors appear to be well tolerated, with a low incidence of significant adverse effects, including hypoglycemia, weight...

  • Financings Roundup.  // BioWorld Today;10/2/2009, Vol. 20 Issue 190, p6 

    This article reports that XOMA Ltd. of Berkeley, California produced 13.9 million U.S. dollars through the sale of 18 million shares to Azimuth Opportunity Ltd. at 77 cents each. The contract of sale is part of an existing committed equity financing facility between Xoma and Azimuth. Proceeds of...

  • ACCORD and type 2 diabetes. Elliott, William T. // Infectious Disease Alert;May2010 Supplement, p1 

    The article discusses research done on the treatment of type 2 diabetes. It references a study published in the March 2010 issue of the "New England Journal of Medicine." The Action to Control Cardiovascular Risk in Diabetics trial is anticipated to change medical practice in the treatment of...

  • 'We are being cautiously optimistic'. KOUL, RAHUL // BioSpectrum;Sep2014, Vol. 12 Issue 9, p27 

    An interview with doctors Ajoy Kumar, chief executive officer (CEO), and Renu Razdan, chief operating officer (COO) of Max Neeman International, is presented. When asked on why the clinical research industry is targeted by activists in India, Kumar says that the guinea pig argument is misleading...

  • Finding ACCORD in the Management of Type 2 Diabetes? Elliott, William T. // Clinical Oncology Alert;May2010 Supplement, p1 

    The article examines the Action to Control Cardiovascular Risk in Diabetics (ACCORD) trial conducted to assess the efficacy of clopidogrel, dexlansoprazole and tamsulosin in treating type 2 diabetes. The trial, published in the March issue of "New England Journal of Medicine," tested the effects...

  • Hope through Research.  // Guía para Personas con Diabetes Tipo 1 y Tipo 2;2013, p61 

    A chapter of the book "Your Guide to Diabetes: Type 1 and 2" is presented which discusses the progress on diabetes research. Topics discussed include the National Institute of Diabetes and Digestive and Kidney Diseases' (NIDDK) support for basic and clinical research in medical centers and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics